Tianjin Weikai Bioengineering

Tianjin Weikai Bioengineering is a clinical-stage biotechnology company based in China, dedicated to the research, development, and commercialization of innovative cell therapies. The company primarily focuses on chimeric antigen receptor T-cell (CAR-T) and T-cell receptor (TCR-T) technologies for the treatment of hematological cancers and solid tumors. Its lead program, WK01, is a CD19-targeted CAR-T therapy currently being evaluated in clinical trials for B-cell malignancies. Weikai Bioengineering maintains integrated R&D and GMP-compliant manufacturing capabilities in Tianjin to support its growing pipeline of next-generation immunotherapies.